Extended Data Fig. 2

Cervical cancer mortality ASR % reductions (A) assuming both women symptomatically-detected and screen-detected for cancer receive status-quo rates for cancer treatment access and (B) assuming both women symptomatically-detected and screen-detected for cancer receive 90% cancer treatment access. The dots represent reductions assuming base case assumptions for test performance and the error bars represent the reductions when assuming the best (upper range) and worst (lower range) primary test performance assumptions as described in Supplementary Table 3. *All positive women treated after assessment of eligibility for ablative treatment. **Triage positive referred to colposcopy. ^^VIA triage positive women treated after assessment of eligibility for ablative treatment. ^HPV16/18 positive women treated after assessment of eligibility for ablative treatment; women positive for HPV types other than HPV 16/18 (‘OHR’) are triaged with VIA.